Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  6/8/2016
Forest Investigative site 100
mi
from
Salt Lake City, UT
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 6/8/2016
Forest Investigative site 100
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  6/8/2016
Forest Investigative Site 1330
mi
from
South Burlington, VT
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 6/8/2016
Forest Investigative Site 1330
mi
from
South Burlington, VT
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  6/8/2016
Forest Investigative Site 1945
mi
from
Newport News, VA
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 6/8/2016
Forest Investigative Site 1945
mi
from
Newport News, VA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  6/8/2016
Forest Investigative site 031
mi
from
Norfolk, VA
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 6/8/2016
Forest Investigative site 031
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  6/8/2016
Forest Investigative Site 1120
mi
from
Bellingham, WA
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 6/8/2016
Forest Investigative Site 1120
mi
from
Bellingham, WA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  6/8/2016
Forest Investigative Site 069
mi
from
Spokane, WA
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 6/8/2016
Forest Investigative Site 069
mi
from
Spokane, WA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  6/8/2016
Forest Investigative Site 1870
mi
from
Tacoma, WA
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 6/8/2016
Forest Investigative Site 1870
mi
from
Tacoma, WA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  6/8/2016
Forest Investigative Site 1555
mi
from
Morgantown, WV
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 6/8/2016
Forest Investigative Site 1555
mi
from
Morgantown, WV
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  6/8/2016
Forest Investigative Site 1991
mi
from
New Lambton,
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 6/8/2016
Forest Investigative Site 1991
mi
from
New Lambton,
Click here to add this to my saved trials
A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects
An Open Label, Partially Randomized, Four-period Study in Healthy Male Subjects to Investigate the Bioavailability and Pharmacokinetics of a Single Dose of AZD7594 When Administered Intravenously, Orally and Inhaled Via Two Different Dry Powder Inhalers (DPI) and a Pressurized Metered-dose Inhaler (pMDI)
Status: Enrolling
Updated:  6/20/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects
An Open Label, Partially Randomized, Four-period Study in Healthy Male Subjects to Investigate the Bioavailability and Pharmacokinetics of a Single Dose of AZD7594 When Administered Intravenously, Orally and Inhaled Via Two Different Dry Powder Inhalers (DPI) and a Pressurized Metered-dose Inhaler (pMDI)
Status: Enrolling
Updated: 6/20/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
A Single−Dose, Fixed-Sequence, Two-Period Study to Evaluate the Absorption, Distribution, Metabolism, Excretion, and Inhaled Bioavailability of TD-4208 Following an IV Infusion and an Oral Dose of [14C]−Labeled TD−4208 in Healthy Male Subjects
Status: Enrolling
Updated:  6/27/2016
Celerion
mi
from
Lincoln, NE
Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
A Single−Dose, Fixed-Sequence, Two-Period Study to Evaluate the Absorption, Distribution, Metabolism, Excretion, and Inhaled Bioavailability of TD-4208 Following an IV Infusion and an Oral Dose of [14C]−Labeled TD−4208 in Healthy Male Subjects
Status: Enrolling
Updated: 6/27/2016
Celerion
mi
from
Lincoln, NE
Click here to add this to my saved trials
Comparison of Two Programs to Encourage Physical Activity in Individuals With Chronic Obstructive Pulmonary Disease
Exercise and Disability in COPD Patients
Status: Enrolling
Updated:  7/28/2016
Wake Forest University
mi
from
Winston-Salem, NC
Comparison of Two Programs to Encourage Physical Activity in Individuals With Chronic Obstructive Pulmonary Disease
Exercise and Disability in COPD Patients
Status: Enrolling
Updated: 7/28/2016
Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Birmingham, AL
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Los Angeles, CA
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
San Diego, CA
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Torrance, CA
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Denver, CO
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Chicago, IL
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Detroit, MI
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Omaha, NE
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Spartanburg, SC
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Spartanburg, SC
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Houston, TX
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated:  8/1/2016
mi
from
Pleven,
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Status: Enrolling
Updated: 8/1/2016
mi
from
Pleven,
Click here to add this to my saved trials
Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  8/4/2016
Chandar Abboy
mi
from
Greenville, SC
Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 8/4/2016
Chandar Abboy
mi
from
Greenville, SC
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Birmingham, AL
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Jasper, AL
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Jasper, AL
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Phoenix, AZ
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Tempe, AZ
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Tempe, AZ
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Berkeley, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Berkeley, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Carmichael, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Carmichael, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Fullerton, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Long Beach, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Los Angeles, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Murrieta, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Murrieta, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Rancho Mirage, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Riverside, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Sacramento, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
San Diego, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
San Jose, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
San Jose, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Sepulveda, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Sepulveda, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Stockton, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Stockton, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Torrance, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Vista, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Vista, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Walnut Creek, CA
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Boulder, CO
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Boulder, CO
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Colorado Springs, CO
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Denver, CO
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/26/2016
GSK Investigational Site
mi
from
Englewood, CO
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/26/2016
GSK Investigational Site
mi
from
Englewood, CO
Click here to add this to my saved trials